For females with myasthenia gravis, pregnancy is not associated with an increased risk of serious flare-ups of the disease, ...
For female participants with myasthenia gravis, pregnancy is not associated with an increased risk of serious flare-ups of ...
Myasthenia gravis is a rare chronic condition that affects an estimated 150 to 200 out of every million people globally.
Argenx (ENXTBR:ARGX) shareholders recently approved Karen Massey as CEO following Tim Van Hauwermeiren's retirement. The company is reiterating its Vision 2030 plan under the new leadership, signaling ...
The label expansion will include adults with AChR-Ab-negative gMG, making efgartigimod the first and only approved treatment for all serotypes of the rare neuromuscular disease.
Label expansion enables serotype-agnostic use of FcRn blockade in adult gMG, positioning both IV Vyvgart and SC Vyvgart Hytrulo as first approved options regardless of antibody status. ADAPT SERON ...
What is MG: An autoimmune neuromuscular disorder where antibodies disrupt nerve-to-muscle communication, causing fluctuating weakness in muscles used for vision, speech, swallowing, movement, and ...
VYVGART and VYVGART Hytrulo are the first and only approved treatments for all serotypes of adult patients living with gMG – anti-AChR-Ab positive, anti-MuSK-Ab positive, anti-LRP4-Ab positive, and ...
(NASDAQ:ARGX) reported first-quarter 2026 results highlighting continued commercial growth for VYVGART and progress across ...
The first quarter 2026 financial results and business update will be discussed during a conference call and webcast presentation today at 2:30 PM CET/8:30 AM ET. A webcast of the live call may be ...
Good morning. My name is David, and I'll be your conference operator today. I would like to welcome everyone to the call. [Operator Instructions] I'd like to introduce Beth DelGiacco, Vice President ...
Argenx Se ( (ARGX)) has shared an announcement. Argenx SE reported strong first-quarter 2026 results on May 7, posting $1.3 billion in global product net sales, a 63% year-on-year increase driven by ...